Hospitals,
insurers and drug companies pitch their ideas on limiting drug price growth to
the Trump administration
By Virgil Dickson | July 21, 2018
HHS received over 3,000 comments on the Trump administration's
Blueprint to Lower Drug Prices, which was released in May. Hospitals, health
insurers and drugmakers had plenty to say on how to address soaring drug
prices. Here are some edited excerpts from those comments.
Health
systems
Ascension
The Food and Drug Administration should create an accelerated pathway to bring generics to the market. There is already a similar pathway for new drugs. This would ensure competition and keep prices down. (Editor's note: Ascension is part of a consortium of providers creating a generic-drug company.)
Baylor Scott & White Health
Create an out-of-pocket spending limit on Part D plans for Medicare beneficiaries, and eliminate cost-sharing for generic and biosimilar drugs. Out-of-pocket spending for patients at the pharmacy and other sites of care have had the unfortunate side effect of increasing medical resource utilization for patients not taking their needed medications.
Henry Ford Health System
Creating stronger liability protections for drug manufacturers for rare adverse events could lower drug prices. Drug companies can and should be liable for known or predictable harms that were not disclosed during FDA review, but should not be liable for adverse events that were not detected in clinical trials because of their rare nature.
The Food and Drug Administration should create an accelerated pathway to bring generics to the market. There is already a similar pathway for new drugs. This would ensure competition and keep prices down. (Editor's note: Ascension is part of a consortium of providers creating a generic-drug company.)
Baylor Scott & White Health
Create an out-of-pocket spending limit on Part D plans for Medicare beneficiaries, and eliminate cost-sharing for generic and biosimilar drugs. Out-of-pocket spending for patients at the pharmacy and other sites of care have had the unfortunate side effect of increasing medical resource utilization for patients not taking their needed medications.
Henry Ford Health System
Creating stronger liability protections for drug manufacturers for rare adverse events could lower drug prices. Drug companies can and should be liable for known or predictable harms that were not disclosed during FDA review, but should not be liable for adverse events that were not detected in clinical trials because of their rare nature.
Drug companies
Amgen
CMS should not move drugs covered under Medicare Part B to Part D, because doing so could severely disrupt patient access.
Gilead
Launch a subscription model in Medicaid for curative therapies. This is an approach that would allow Medicaid to pay an upfront annual fee, based on expected annual patient volumes, for an unlimited number of patients over multiple years.
Sanofi
Create a new safe harbor for value-based arrangements in which drug payment is based on outcomes. Such a safe harbor should protect services that are aimed at encouraging better clinical outcomes, and new and emerging technologies that complement treatment.
CMS should not move drugs covered under Medicare Part B to Part D, because doing so could severely disrupt patient access.
Gilead
Launch a subscription model in Medicaid for curative therapies. This is an approach that would allow Medicaid to pay an upfront annual fee, based on expected annual patient volumes, for an unlimited number of patients over multiple years.
Sanofi
Create a new safe harbor for value-based arrangements in which drug payment is based on outcomes. Such a safe harbor should protect services that are aimed at encouraging better clinical outcomes, and new and emerging technologies that complement treatment.
Health
insurers
Aetna
Don't end drug rebates. Savings that health plans achieved through them will be lost—leading to higher prices.
Anthem
Drug manufacturers should include list price in their advertisements. This is a critical detail that consumers need in order to make informed choices.
Humana
Permit Medicare Advantage plans to perform prior authorization for Part B Drugs. Medicare could save as much as 23% on immunology drugs like Remicade, Stelara, Simponi in 2019 if the idea were adopted.
Don't end drug rebates. Savings that health plans achieved through them will be lost—leading to higher prices.
Anthem
Drug manufacturers should include list price in their advertisements. This is a critical detail that consumers need in order to make informed choices.
Humana
Permit Medicare Advantage plans to perform prior authorization for Part B Drugs. Medicare could save as much as 23% on immunology drugs like Remicade, Stelara, Simponi in 2019 if the idea were adopted.
Virgil Dickson reports from
Washington on the federal regulatory agencies. His experience before joining
Modern Healthcare in 2013 includes serving as the Washington-based
correspondent for PRWeek and as an editor/reporter for FDA News. Dickson earned
a bachelor's degree from DePaul University in 2007.
Im no expert, but I believe you just made an excellent point. You certainly fully understand what youre speaking about, and I can truly get behind that. Will Blue Cross Blue Shield cover Drug Rehab?
ReplyDelete